Pasar al contenido principal

Biosensores nanofotónicos para el diagnóstico y gestión clínica de infecciones bacterianas en el punto de atención

PLEC2021-007739

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i en Líneas Estratégicas
Año convocatoria 2021
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACIÓ INSTITUT CATALÀ DE NANOCIÈNCIA I NANOTECNOLOGIA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Targeted bacterial conjugation mediated by synthetic cell-to-cell adhesions

  • Robledo, Marta
  • Álvarez, Beatriz
  • Cuevas, Ana
  • González, Sheila
  • Ruano-Gallego, David
  • Fernández, Luis Ángel
  • Cruz, Fernando de la
Genetic interventions on microbiomes, for clinical or biotechnological purposes, remain challenging. Conjugation-based delivery of genetic cargo is still unspecific and limited by low conjugation rates. Here we report an approach to overcome these problems, based on a synthetic bacterial adhesion system. Mating assemblers consist on a synthetic adhesion formed by the expression on the surface of donor and target cells of specific nanobodies (Nb) and their cognate antigen (Ag). The Nb–Ag bridge increased 1–3 logs transfer of a variety of plasmids, especially in liquid media, confirming that cell-cell docking is a main determinant limiting mating efficiency. Synthetic cell-to-cell adhesion allows efficient conjugation to targeted recipients, enhancing delivery of desired genes to a predefined subset of prey species, or even specific pathogenic strains such as enterohemorrhagic Escherichia coli (EHEC), within a bacterial community. The synthetic conjugation enhancer presented here optimizes plasmid delivery by selecting the target hosts with high selectivity., Spanish Science and Innovation Ministry (MCIN) [PID2020-117923GB-I00 to F.d.l.C.]; MCIN/AEI and FEDER [BIO2017-89081-R]; MCIN/AEI and NextGeneration EU/PRTR [PLEC2021-007739 to L.A.F.]., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A tuneable genetic switch for tight control of tac promoters in Escherichia coli boosts expression of synthetic injectisomes

  • Asensio-Calavia, Alejandro
  • Ceballos-Munuera, Álvaro
  • Méndez-Pérez, Almudena
  • Álvarez, Beatriz
  • Fernández, Luis Ángel
Biosafety of engineered bacteria as living therapeutics requires a tight regulation to control the specific delivery of protein effectors, maintaining minimum leakiness in the uninduced (OFF) state and efficient expression in the induced (ON) state. Here, we report a three repressors (3R) genetic circuit that tightly regulates the expression of multiple tac promoters (Ptac) integrated in the chromosome of E. coli and drives the expression of a complex type III secretion system injectisome for therapeutic protein delivery. The 3R genetic switch is based on the tetracycline repressor (TetR), the non-inducible lambda repressor cI (ind-) and a mutant lac repressor (LacIW220F) with higher activity. The 3R switch was optimized with different protein translation and degradation signals that control the levels of LacIW220F. We demonstrate the ability of an optimized switch to fully repress the strong leakiness of the Ptac promoters in the OFF state while triggering their efficient activation in the ON state with anhydrotetracycline (aTc), an inducer suitable for in vivo use. The implementation of the optimized 3R switch in the engineered synthetic injector E. coli (SIEC) strain boosts expression of injectisomes upon aTc induction, while maintaining a silent OFF state that preserves normal growth in the absence of the inducer. Since Ptac is a commonly used promoter, the 3R switch may have multiple applications for tight control of protein expression in E. coli. In addition, the modularity of the 3R switch may enable its tuning for the control of Ptac promoters with different inducers., Future and Emerging Technologies, Grant/Award Number: FET Open 965018-BIOCELLPHE; MCIN/AEI and NextGeneration EU/ PRTR, Grant/Award Number: PLEC2021-007739; Ministerio de Ciencia e Innovación, Grant/ Award Number: BIO2017-89081-R; PhD contracts, Grant/Award Number: FPI BES-2015-073850, FPU16/01427 and FPU18/03199, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Targeting plasmid-encoded proteins that contain immunoglobulin-like domains to combat antimicrobial resistance

  • Prieto, Alejandro
  • Miró, Luïsa
  • Margolles, Yago
  • Bernabeu, Manuel
  • Salguero, David
  • Merino, Susana
  • Tomas, Joan
  • Corbera, Juan Alberto
  • Perez-Bosque, Anna
  • Huttener, Mario
  • Fernández, Luis Ángel
  • Juarez, Antonio
Antimicrobial resistance (AMR) poses a significant threat to human health. Although vaccines have been developed to combat AMR, it has proven challenging to associate specific vaccine antigens with AMR. Bacterial plasmids play a crucial role in the transmission of AMR. Our recent research has identified a group of bacterial plasmids (specifically, IncHI plasmids) that encode large molecular mass proteins containing bacterial immunoglobulin-like domains. These proteins are found on the external surface of the bacterial cells, such as in the flagella or conjugative pili. In this study, we show that these proteins are antigenic and can protect mice from infection caused by an AMR Salmonella strain harboring one of these plasmids. Furthermore, we successfully generated nanobodies targeting these proteins, that were shown to interfere with the conjugative transfer of IncHI plasmids. Considering that these proteins are also encoded in other groups of plasmids, such as IncA/C and IncP2, targeting them could be a valuable strategy in combating AMR infections caused by bacteria harboring different groups of AMR plasmids. Since the selected antigens are directly linked to AMR itself, the protective effect extends beyond specific microorganisms to include all those carrying the corresponding resistance plasmids., This work was supported by grants from Fundació 'La Marató TV3,' Spain (project 201818 10), CERCA Program/Generalitat de Catalunya to AJ, PID2021-­ 124676NB-­ I00 from the Ministerio de Economía, Industria y Competitividad to SM and JT. Work in the laboratory of LAF is supported by grants PLEC2021-­ 007739 from MCIN/AEI NextGeneration EU/ PRTR and FET Open 965018-­ BIOCELLPHE from the European Union’s Horizon 2020 Future and Emerging Technologies research and innovation program. LM and APB are members of the Institut de Recerca en Nutrició, i Seguretat Alimentària (INSA-­ UB), which is recognized as a Maria de Maeztu Unit of Excellence and funded by MICIN/AEI/ FEDER (CEX2021-­ 001234-­ M)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Integrating immune library probing with structure-based computational design to develop potent neutralizing nanobodies against emerging SARS-CoV-2 variants

  • Cerdán, Lidia
  • Silva, Katixa
  • Rodríguez-Martín, Daniel
  • Pérez, Patricia
  • Noriega, María A
  • Esteban Martín, Ana
  • Gutiérrez-Adán, Alfonso
  • Margolles, Yago
  • Corbera, Juan A
  • Martín-Acebes, Miguel A.
  • García-Arriaza, Juan
  • Fernández-Recio, Juan
  • Fernández, Luis A.
  • Casasnovas, José M.
To generate antibodies (Abs) against SARS-CoV-2 emerging variants, we integrated multiple tools and engineered molecules with excellent neutralizing breadth and potency. Initially, the screening of an immune library identified a nanobody (Nb), termed Nb4, specific to the receptor-binding domain (RBD) of the Omicron BA.1 variant. A Nb4-derived heavy chain antibody (hcAb4) recognized the spike (S) of the Wuhan, Beta, Delta, Omicron BA.1, and BA.5 SARS-CoV-2 variants. A high-resolution crystal structure of the Nb4 variable (VHH) domain in complex with the SARS-CoV-2 RBD (Wuhan) defined the Nb4 binding mode and interface. The Nb4 VHH domain grasped the RBD and covered most of its outer face, including the core and the receptor-binding motif (RBM), which was consistent with hcAb4 blocking RBD binding to the SARS-CoV-2 receptor. In mouse models, a humanized hcAb4 showed therapeutic potential and prevented the replication of SARS-CoV-2 BA.1 virus in the lungs of the animals. In vitro, hcAb4 neutralized Wuhan, Beta, Delta, Omicron BA.1, and BA.5 viral variants, as well as the BQ.1.1 subvariant, but showed poor neutralization against the Omicron XBB.1.5. Structure-based computation of the RBD-Nb4 interface identified three Nb4 residues with a reduced contribution to the interaction with the XBB.1.5 RBD. Site-saturation mutagenesis of these residues resulted in two hcAb4 mutants with enhanced XBB.1.5 S binding and virus neutralization, further improved by mutant Nb4 trimers. This research highlights an approach that combines library screening, Nb engineering, and structure-based computational predictions for the generation of SARS-CoV-2 Omicron-specific Abs and their adaptation to emerging variants., The work was supported by the Ministerio de Ciencia, Innovación yUniversidades [202020E079, 202120E079, 202340E181, CNS2022-135511, PID2020-114481RB-I00, PID2022-143215OB-I00 andPLEC2021-007739]; NextGenerationEU [SGL 2103047, SGL 2103051and SGL 2103053]; HORIZON EUROPE Framework Programme[101130574-ALADDIN], Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Therapeutic Drug Monitoring of Amikacin and Colistin in Patients with Multidrug-Resistant Gram-Negative Infections Using a Portable Plasmonic Biosensor

  • Astua, Alejandro
  • Estévez, M. Carmen
  • Luque, Sonia
  • Grau, Santiago
  • Sorlí, Luisa
  • Montero, Milagro
  • Horcajada, Juan P.
  • Lechuga, Laura M.
Innovative diagnostic tools that enhance antibiotic routine monitoring can improve the management of infections caused by antibiotic-resistant bacteria. Therapeutic drug monitoring (TDM) involves measuring drug levels in the patient bloodstream to ensure optimal efficacy and safety, particularly for drugs with a narrow therapeutic index (TI), assisting in dosage control and toxicity risk management. Amikacin (AK) and colistin (CS) are crucial antibiotics for treating multidrug-resistant (MDR) bacteria but they have side effects that require a precise TDM to try to minimize them. Current analytical techniques like immunoassays, high-performance liquid chromatography (HPLC), and liquid chromatography-mass spectrometry (LC-MS) are gold standards for the antibiotic analysis, but they may require transferring the human samples to centralized facilities, delaying crucial results and turnaround time. In contrast, plasmonic biosensors offer advantages for clinical diagnostics, enabling real-time drug detection with minimal sample volume and processing, being ideal for point-of-care applications. We have implemented plasmonic biosensors to quantify and rapidly monitor blood levels of amikacin and colistin. The biosensors provide high specificity and sensitivity, with limits of detection (LOD) of 0.92 ng/mL (1.57 nM) for amikacin and 9.11 pg/mL (7.88 pM) for colistin in blood serum. Statistics analyses demonstrated a strong correlation between the biosensor evaluation and the standard analytical methods (Spearman's correlation coefficient of 0.9171 (p-value < 0.001) and 0.7435 (p-value = 0.04) for amikacin and colistin, respectively). Our plasmonic biosensors offer in addition, simplicity, portability, and label-free evaluation, with multiplexed capabilities. The rapid turnaround of results in under 20 min, coupled with minimal sample processing, enhances the feasibility of personalized TDM, supporting tailored treatment strategies that can improve patient outcomes. This work lays the foundation for creating an integrated point-of-care biosensor platform for effectively performing TDM of antibiotics and other drugs in real-time at the patient's bedside in clinical settings., We acknowledge the financial support received for the PHITBAC project (PLEC2021-007739), funded by MCIN/AEI/10.13039/501100011033 and the European Union NextGenerationEU/PRTR. A.A. acknowledges the financial support from the European Union’s Horizon 2020 Research and Innovation Program under the Marie Skłodowska-Curie grant agreement no. 754397. The ICN2 is supported by the Severo Ochoa Centres of Excellence program, grant CEX2021-001214-S, funded by MCIN/AEI/10.13039.501100011033. The nanoB2A is a consolidated research group (‘Grup de Recerca’) of the Generalitat de Catalunya and is supported by the Departament de Recerca i Universitats de la Generalitat de Catalunya (no. 2021 SGR 00456)., With funding from the Spanish government through the "Severo Ochoa Centre of Excelence" accreditation (CEX2021-001214-S), Peer reviewed